Jianqing Xu Selected Research

Interferon Type I

1/2022	Angiotensin-Converting Enzyme 2 Potentiates SARS-CoV-2 Infection by Antagonizing Type I Interferon Induction and Its Down-Stream Signaling Pathway.
1/2022	HIV-1 Vif suppresses antiviral immunity by targeting STING.
1/2020	IFN-κ suppresses the replication of influenza A viruses through the IFNAR-MAPK-Fos-CHD6 axis.
1/2018	AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling.
8/2017	Zika virus infects renal proximal tubular epithelial cells with prolonged persistency and cytopathic effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jianqing Xu Research Topics

Disease

54	Infections 04/2024 - 03/2002
22	Neoplasms (Cancer) 07/2023 - 09/2010
20	COVID-19 03/2024 - 01/2020
19	Human Influenza (Influenza) 03/2024 - 11/2006
15	Vaccinia 08/2021 - 05/2003
8	Virus Diseases (Viral Diseases) 03/2024 - 01/2016
8	Inflammation (Inflammations) 11/2021 - 01/2012
6	Acquired Immunodeficiency Syndrome (AIDS) 01/2018 - 01/2005
5	Tuberculosis (Tuberculoses) 04/2024 - 01/2015
5	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 04/2017
4	Persistent Infection 11/2017 - 01/2005
3	Hypoxia (Hypoxemia) 01/2023 - 10/2020
3	HIV Infections (HIV Infection) 09/2022 - 01/2018
3	Pneumonia (Pneumonitis) 11/2021 - 01/2014
3	Communicable Diseases (Infectious Diseases) 01/2021 - 09/2008
3	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 01/2014
3	Zika Virus Infection 01/2020 - 08/2017
2	Pulmonary Tuberculosis 04/2024 - 11/2023
2	Reinfection 12/2023 - 01/2022
2	Bites and Stings (Sting) 01/2023 - 01/2022
2	Rabies (Hydrophobia) 01/2023 - 01/2022
2	Experimental Melanoma 01/2023 - 07/2015
2	Disease Progression 01/2021 - 02/2016
2	Cough 01/2021 - 08/2020
2	Astrocytoma (Pilocytic Astrocytoma) 01/2020 - 04/2014
2	Carcinoma (Carcinomatosis) 01/2020 - 01/2015
2	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 02/2016
2	Influenza in Birds (Avian Flu) 09/2016 - 01/2012
2	Glioma (Gliomas) 04/2014 - 01/2014
1	Pain (Aches) 01/2024
1	Respiratory Tract Infections (Respiratory Tract Infection) 12/2023
1	Post-Acute COVID-19 Syndrome 12/2023
1	Fatigue 12/2023
1	Pancreatitis 11/2023
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 07/2023
1	Hypoparathyroidism 05/2023
1	Secondary Hyperparathyroidism 05/2023

Drug/Important Bio-Agent (IBA)

32	VaccinesIBA 03/2024 - 01/2005
19	Proteins (Proteins, Gene)FDA Link 01/2023 - 05/2008
15	AntigensIBA 01/2023 - 05/2003
12	CytokinesIBA 01/2024 - 01/2014
11	Antiviral Agents (Antivirals)IBA 03/2024 - 09/2007
11	AntibodiesIBA 01/2022 - 01/2011
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 02/2016
7	Neutralizing AntibodiesIBA 03/2024 - 11/2012
7	Messenger RNA (mRNA)IBA 01/2024 - 01/2017
7	DNA (Deoxyribonucleic Acid)IBA 08/2021 - 11/2006
7	MicroRNAs (MicroRNA)IBA 01/2021 - 02/2016
5	RNA (Ribonucleic Acid)IBA 04/2024 - 08/2017
5	Immunoglobulin G (IgG)IBA 09/2022 - 12/2007
5	Hemagglutinins (Hemagglutinin)IBA 01/2022 - 12/2013
5	Interferon Type IIBA 01/2022 - 08/2017
5	Peptides (Polypeptides)IBA 01/2018 - 05/2003
5	DNA VaccinesIBA 12/2017 - 06/2007
4	Chimeric Antigen ReceptorsIBA 01/2023 - 10/2020
4	InterferonsIBA 01/2022 - 01/2014
4	Monoclonal AntibodiesIBA 10/2020 - 01/2017
4	EpitopesIBA 01/2020 - 05/2013
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 04/2024 - 12/2007
3	N-methyl-valyl-amiclenomycin (BA 2)IBA 04/2024 - 09/2023
3	Immunoglobulin A (IgA)IBA 03/2024 - 12/2007
3	Long Noncoding RNAIBA 09/2023 - 04/2017
3	Therapeutic UsesIBA 04/2023 - 06/2017
3	InterleukinsIBA 01/2023 - 09/2015
3	EnzymesIBA 02/2022 - 01/2017
3	Tyrosine (L-Tyrosine)FDA Link 01/2022 - 10/2015
3	Glycoproteins (Glycoprotein)IBA 01/2022 - 01/2016
3	Viral RNAIBA 01/2021 - 02/2014
3	Recombinant DNA (Recombinant DNA Research)IBA 01/2019 - 05/2014
2	COVID-19 VaccinesIBA 09/2023 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2022
2	Interleukin-13IBA 01/2023 - 10/2015
2	Toll-Like Receptor 4IBA 01/2023 - 01/2017
2	NucleosidesIBA 01/2023 - 01/2022
2	mRNA VaccinesIBA 01/2023 - 01/2022
2	LipopolysaccharidesIBA 09/2022 - 01/2017
2	ImmunosorbentsIBA 02/2022 - 01/2017
2	HymecromoneIBA 02/2022 - 01/2022
2	Hyaluronic Acid (Hyaluronan)IBA 02/2022 - 01/2022
2	Codon (Codons)IBA 01/2022 - 01/2022
2	GP 140IBA 08/2021 - 06/2009
2	HLA-DR Antigens (HLA-DR)IBA 01/2021 - 05/2003
2	LigandsIBA 11/2020 - 06/2017
2	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2020 - 01/2018
2	Mechanistic Target of Rapamycin Complex 1IBA 11/2017 - 06/2017
2	Anti-Infective Agents (Microbicides)IBA 02/2016 - 01/2012
2	DermaVirIBA 01/2005 - 01/2005
1	Amino Acids FDA Link 03/2024
1	Asialoglycoprotein ReceptorIBA 02/2024
1	Small Interfering RNA (siRNA)IBA 02/2024
1	SuspensionsIBA 01/2024
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2023
1	P-selectin ligand proteinIBA 11/2023
1	Transferrin Receptors (Transferrin Receptor)IBA 07/2023
1	thiazolyl blueIBA 07/2023

Therapy/Procedure

11	Immunotherapy 04/2024 - 01/2016
11	Therapeutics 11/2023 - 03/2002
4	Drug Therapy (Chemotherapy) 01/2023 - 01/2014
1	Aftercare (After-Treatment) 02/2024
1	Parathyroidectomy 05/2023